CN111588849A - 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 - Google Patents

使用贝那利珠单抗增加哮喘患者用力呼气量的方法 Download PDF

Info

Publication number
CN111588849A
CN111588849A CN202010450690.6A CN202010450690A CN111588849A CN 111588849 A CN111588849 A CN 111588849A CN 202010450690 A CN202010450690 A CN 202010450690A CN 111588849 A CN111588849 A CN 111588849A
Authority
CN
China
Prior art keywords
benralizumab
ser
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010450690.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·沃德
L·罗斯科斯
王冰
D·雷布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN111588849A publication Critical patent/CN111588849A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
CN202010450690.6A 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 Pending CN111588849A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
CN201480045047.8A CN105451769A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480045047.8A Division CN105451769A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Publications (1)

Publication Number Publication Date
CN111588849A true CN111588849A (zh) 2020-08-28

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010450690.6A Pending CN111588849A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法
CN201480045047.8A Pending CN105451769A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480045047.8A Pending CN105451769A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3520811B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN111588849A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2733602T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE053627T2 (https=)
LT (2) LT3033104T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3033104T3 (https=)
PT (2) PT3033104T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT202100152T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306956B2 (en) 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN103223167A (zh) * 2007-05-14 2013-07-31 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｉｌ－５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
RU2578468C2 (ru) * 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
AU2014306956B2 (en) 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103223167A (zh) * 2007-05-14 2013-07-31 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHEL LAVIOLETTE等: "effects of benralizumab on airway ensinophils in asthmatic patients with sputum eosinophilia", 《JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》 *

Also Published As

Publication number Publication date
WO2015023507A8 (en) 2015-09-24
PL3033104T3 (pl) 2019-09-30
CN105451769A (zh) 2016-03-30
RU2016108809A3 (https=) 2018-06-18
LT3033104T (lt) 2019-06-25
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
SMT202100152T1 (it) 2021-05-07
JP2020125304A (ja) 2020-08-20
JP2016527325A (ja) 2016-09-08
ME03403B (me) 2020-01-20
HK1225300A1 (en) 2017-09-08
JP2022120010A (ja) 2022-08-17
BR112016002317A2 (pt) 2017-12-12
LT3520811T (lt) 2021-03-25
RS58711B1 (sr) 2019-06-28
SI3520811T1 (sl) 2021-04-30
PL3520811T3 (pl) 2021-08-02
DK3520811T3 (da) 2021-03-22
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
TR201907907T4 (tr) 2019-06-21
HRP20190920T1 (hr) 2019-07-12
JP6746496B2 (ja) 2020-08-26
SMT201900311T1 (it) 2019-07-11
EP3033104A2 (en) 2016-06-22
EP3875487A1 (en) 2021-09-08
EP4579236A3 (en) 2025-09-17
EP3520811A1 (en) 2019-08-07
US9441046B2 (en) 2016-09-13
HK1222559A1 (zh) 2017-07-07
HUE053627T2 (hu) 2021-07-28
KR102337599B1 (ko) 2021-12-10
BR112016002317A8 (pt) 2018-06-12
CY1124399T1 (el) 2022-07-22
EP3033104A4 (en) 2017-03-22
EP4636400A3 (en) 2025-12-24
EP3033104B1 (en) 2019-04-03
SI3033104T1 (sl) 2019-06-28
ES2866426T3 (es) 2021-10-19
PT3033104T (pt) 2019-06-27
MX2016001384A (es) 2016-08-03
US20150044203A1 (en) 2015-02-12
AU2020201277A1 (en) 2020-03-12
ES2733602T3 (es) 2019-12-02
RU2703568C2 (ru) 2019-10-21
CY1122033T1 (el) 2020-10-14
CA2917603C (en) 2023-05-16
CA2917603A1 (en) 2015-02-19
RS61565B1 (sr) 2021-04-29
EP4636400A2 (en) 2025-10-22
KR20160043049A (ko) 2016-04-20
DK3033104T3 (da) 2019-06-17
WO2015023507A2 (en) 2015-02-19
AU2014306959A1 (en) 2016-02-04
EP3520811B1 (en) 2020-12-30
HRP20210406T1 (hr) 2021-04-30
MX381102B (es) 2025-03-12
MX2021003826A (es) 2021-05-27
SG11201600483QA (en) 2016-02-26
EP4579236A2 (en) 2025-07-02
JP2024129140A (ja) 2024-09-26
PT3520811T (pt) 2021-03-15

Similar Documents

Publication Publication Date Title
CN111588849A (zh) 使用贝那利珠单抗增加哮喘患者用力呼气量的方法
CN111588848A (zh) 使用贝那利珠单抗降低哮喘恶化率的方法
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40035228A (en) Methods for improving asthma symptoms using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40035227

Country of ref document: HK